Analysis-Can nicotine pouches drive Big Tobacco’s future beyond cigarettes?

Fast-growing nicotine pouches have become a key focus for Big Tobacco companies seeking a future beyond cigarettes. Brands like Philip Morris International's Zyn and British American Tobacco's Velo show strong growth potential, attractive margins, and lighter regulation compared to other nicotine alternatives. As cigarette sales decline, investors are closely watching whether these pouches can gain broader acceptance and become a significant profit engine.

However, the category faces two major challenges. First, convincing smokers in markets without a tradition of oral nicotine products to switch to pouches is difficult. Second, sustaining growth becomes complicated as regulators become more concerned about youth uptake and marketing practices. While BAT predicts pouch revenue will reach £11 billion by 2030, it still represents only a fraction of the company's U.S. and European businesses.

Despite these hurdles, pouches appear promising. They generate higher gross profit per unit than many smoking alternatives and can be used in places where other products are restricted due to their lack of smoke or vapor. Moreover, they may offer smokers a less harmful alternative compared to traditional cigarettes, although they are not entirely risk-free.

Regulators and public health groups, however, remain wary of pouches, especially due to aggressive marketing and high nicotine strengths that appeal to new users. While some countries have banned pouches outright or introduced restrictions, the World Health Organization warns that many markets still lack specific regulations governing these products.

For investors, the central question remains: Can pouches match the popularity of other products in markets without established oral nicotine traditions? Consumers in many countries may be more accustomed to inhaling nicotine rather than consuming it orally, which could be a significant barrier to wider adoption. Pouches currently account for a small portion of total volumes for companies like Philip Morris, indicating that a diverse portfolio of alternatives will likely be essential for long-term success in this evolving market.